Fly News Breaks for February 28, 2020
Feb 28, 2020 | 05:29 EDT
Nektar Therapeutics' earnings call last night included several notable updates, namely the confirmation that PD-1 relapsed lung data will be presented by year-end, the pivotal melanoma overall response rate analysis could include a look at complete response rate, which if at least 25%, could be approvable, and that the company will now evaluate the bempeg/262 doublet and bempeg/262/nivo triplet in melanoma, Piper Sandler analyst Tyler Van Buren tells investors in a research note. The analyst believes Nektar shares will end the year higher from here as we head towards the first pivotal bempeg readout. He reiterates an Overweight rating on the name with a $35 price target.
News For NKTR From the Last 2 Days
There are no results for your query NKTR